VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells

Molecular Cancer Research

Volumn 12, Issue 8, 2014, Pages 1166-1180

  Solomon, Joshua D ^a   Heitzer, Marjet D ^b   Liu, Teresa T ^b   Beumer, Jan H ^a   Parise, Robert A ^a   Normolle, Daniel P ^c   Leach, Damien A ^d   Buchanan, Grant ^d   DeFranco, Donald B ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL RECEPTOR; MESSENGER RNA; PAXILLIN; PROTEIN HIC 5; SCAFFOLD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; 1,25-DIHYDROXY-16,23-DIENE VITAMIN D3; ANDROGEN; CALCITRIOL RECEPTOR; COLECALCIFEROL; COLECALCIFEROL 24 HYDROXYLASE; DNA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; GROWTH INHIBITION; LNCAP CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; STROMA CELL; TRANSCRIPTION INITIATION SITE; TUMOR MICROENVIRONMENT; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; PROSTATIC NEOPLASMS; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANDROGENS; CELL LINE, TUMOR; CHOLECALCIFEROL; DNA-BINDING PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STROMAL CELLS; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION; VITAMIN D3 24-HYDROXYLASE;

EID: 84905994090     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0395     Document Type: Article

References (74)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Droz J-P, Fléchon A, Terret C. Prostate cancer: management of advanced disease. Ann Oncol 2002;13:89-94. (Pubitemid 35363758)
3. Schwartz GG, Hanchette CL. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control 2006;17:1091-101. (Pubitemid 44290774)
4. Nair-Shalliker V, Smith DP, Egger S, Hughes AM, Kaldor JM, Clements M, et al. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. Int J Cancer 2012;131:E726-32.
5. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, Penney KL, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012;104:690-9.
6. Bonilla C, Hooker S, Mason T, Bock CH, Kittles RA. Prostate cancer susceptibility loci identified on chromosome 12 in African Americans. PLoS ONE 2011;6:e16044.
7. Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT Jr., Anderson RR, et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 1980;210:203-5. (Pubitemid 11252464)
8. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 2011;29:2378-85.
9. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer - ready for prime time? N Engl J Med 2011;364:1385-7.
10. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25:669-74. (Pubitemid 350002922)
11. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29:2191-8.
12. Wagner D, Trudel D, Van der Kwast T, Nonn L, Giangreco AA, Li D, et al. Randomized clinical trial of vitamin d3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab 2013;98:1498-507.
13. Flores O, Wang Z, Knudsen KE, Burnstein KL. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 2010;151:896-908.
14. Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862-8. (Pubitemid 37452267)
15. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000;141:10-7. (Pubitemid 32260340)
16. Kizildag S, Ates H, Kizildag S. Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21. Ann Hematol 2010;89:1-7.
17. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1a,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002;1:667-77.
18. Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, et al. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 2001;49:224-33. (Pubitemid 33062620)
19. Swami S, Krishnan AV, WangJY, Jensen K, Horst R, Albertelli MA, et al. Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 2012;153:2576-87.
20. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1α,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 2001;165:1319-24. (Pubitemid 32210283)
21. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-κB pathways. Prostate 2009;69:480-93.
22. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ. 1α,25- Dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress NF-κB-mediated interleukin-8 gene expression. Eur J Biochem 1997;250:63-71. (Pubitemid 27504583)
23. Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013;153:601-13.
24. Yanagi Y, Suzawa M, Kawabata M, Miyazono K, Yanagisawa J, Kato S. Positive and negative modulation of vitamin D receptor function by transforming growth factor-β signaling through SMAD proteins. J Biol Chem 1999;274:12971-4.
25. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012;19: R187-204.
26. Sugimura Y, Foster BA, Hom YK, Lipschutz JH, Rubin JS, Finch PW, et al. Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 1996;40:941-51. (Pubitemid 26387216)
27. Planz B, Wang Q, Kirley SD, Lin CW, McDougal WS. Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen. J Urol 1998;160:1850-5. (Pubitemid 128746774)
28. Hayward SW, Cunha GR, Dahiya R. Normal development and carcinogenesis of the prostate: a unifying hypothesis. Ann N Y Acad Sci 1996;784:50-62.
29. Grossfeld GD, Hayward SW, Tlsty TD, Cunha GR. The role of stroma in prostatic carcinogenesis. Endocr Relat Cancer 1998;5:253-70. (Pubitemid 29030266)
30. Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 1997;232:208-15. (Pubitemid 27194032)
31. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, Ayala GE, et al. The role of transforming growth factor-β-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Res 2009;69:7111-20.
32. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83. (Pubitemid 33065339)
33. Wang J, Dodd C, Shankowsky HA, Scott PG, Tredget EE. Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest 2008;88:1278-90.
34. Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol 2002;191:208-16. (Pubitemid 34273469)
35. Vollmer G, Michna H, Schneider MR, Knuppen R. Stromal expression of tenascin is inversely correlated to epithelial differentiation of hormone dependent tissues. J Steroid Biochem Mol Biol 1994;48:487-94. (Pubitemid 24171875)
36. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998;4:963-71. (Pubitemid 28183398)
37. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008;9:628-38.
38. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000;60:6253-8.
39. Kaminski A, Hahne JC, Haddouti el M, Florin A, Wellmann A, Wernert N. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Mol Med 2006;18:941-50.
40. Shibanuma M, Mashimo J, Mita A, Kuroki T, Nose K. Cloning from a mouse osteoblastic cell line of a set of transforming growth factor β1-regulated genes, one of which seems to encode a follistatin-related polypeptide. Eur J Biochem 1993;217:13-9. (Pubitemid 23305265)
41. Shibanuma M, Mashimo J, Kuroki T, Nose K. Characterization of the TGFβ1-inducible hic-5 gene that encodes a putative novel zinc finger protein and its possible involvement in cellular senescence. J Biol Chem 1994;269:26767-74.
42. Heitzer MD, DeFranco DB. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 2006;66:7326-33. (Pubitemid 44197715)
43. Dawid IB, Breen JJ, Toyama R. LIM domains: multiple roles as adapters and functional modi fiers in protein interactions. Trends Genet 1998;14:156-62. (Pubitemid 28206396)
44. Deakin NO, Turner CE. Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis. Mol Biol Cell 2011;22:327-41.
45. Heitzer MD, DeFranco DB. Mechanism of action of Hic-5/androgen receptor activator 55, a LIM domain-containing nuclear receptor coactivator. Mol Endocrinol 2006;20:56-64. (Pubitemid 43011670)
46. Xie S, Ni J, Lee YF, Liu S, Li G, Shyr CR, et al. Increased acetylation in the DNA-binding domain of TR4 nuclear receptor by the coregulator ARA55 leads to suppression of TR4 transactivation. J Biol Chem 2011;286:21129-36.
47. Shibanuma M, Kim-Kaneyama JR, Sato S, Nose K. A LIM protein, Hic-5, functions as a potential coactivator for Sp1. J Cell Biochem 2004;91:633-45.
48. Wang H, Song K, Sponseller TL, Danielpour D. Novel function of androgen receptor-associated protein 55/Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 2005;280:5154-62. (Pubitemid 40279985)
49. Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene 2011;30:167-77.
50. Zhang Q, Kanterewicz B, Buch S, Petkovich M, Parise R, Beumer J, et al. CYP24 inhibition preserves 1α,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Mol Cell Endocrinol 2012;355:153-61.
51. Kumar R, Iachini DN, Neilsen PM, Kaplan J, Michalakas J, Anderson PH, et al. Systematic characterisation of the rat and human CYP24A1 promoter. Mol Cell Endocrinol 2010;325:46-53.
52. Ellison TI, Dowd DR, MacDonald PN. Calmodulin-dependent kinase IV stimulates vitamin D receptor-mediated transcription. Mol Endocrinol 2005;19:2309-19. (Pubitemid 41252824)
53. Need EF, Scher HI, Peters AA, Moore NL, Cheong A, Ryan CJ, et al. A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 2009;150:2674-82.
54. Schug J. Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics 2008;Chapter 2:Unit 2.6.
55. Searle SR. Linear models for unbalanced data. Wiley; New York 1987.
56. Keene ON. The log transformation is special. Stat Med 1995;14:811-9.
57. Wang H, Song K, Krebs TL, Yang J, Danielpour D. Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene 2008;27:6791-805.
58. Dabiri G, Tumbarello DA, Turner CE, Van de Water L. Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-β1 autocrine loop. J Invest Dermatol 2008;128:2518-25.
59. Chodankar R, Wu DY, Schiller BJ, Yamamoto KR, Stallcup MR. Hic-5 is a transcription coregulator that acts before and/or after glucocorticoid receptor genome occupancy in a gene-selective manner. Proc Natl Acad Sci U S A 2014;111:4007-12.
60. Staal A, van den Bemd GJ, Birkenhager JC, Pols HA, van Leeuwen JP. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway. Bone 1997;20:237-43. (Pubitemid 27141835)
61. Pedrozo HA, Boyan BD, Mazock J, Dean DD, Gomez R, Schwartz Z. TGFβ1 regulates 25-hydroxyvitamin D3 1α- and 24-hydroxylase activity in cultured growth plate chondrocytes in a maturation-dependent manner. Calcif Tissue Int 1999;64:50-6. (Pubitemid 29024629)
62. Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010;151:4301-12.
63. Chen KS, DeLuca HF. Cloning of the human 1α,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995;1263:1-9.
64. Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL, et al. Altered VDR-mediated transcriptional activity in prostate cancer stroma. J Steroid Biochem Mol Biol 2007;103:731-6. (Pubitemid 46401318)
65. Gobel F, Taschner S, Jurkin J, Konradi S, Vaculik C, Richter S, et al. Reciprocal role of GATA-1 and vitamin D receptor in human myeloid dendritic cell differentiation. Blood 2009;114:3813-21.
66. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:997-1003.
67. Chen J, Olivares-Navarrete R, Wang Y, Herman TR, Boyan BD, Schwartz Z. Protein-disulfide isomerase-associated 3 (Pdia3) mediates the membrane response to 1,25-dihydroxyvitamin D3 in osteoblasts. J Biol Chem 2010;285:37041-50.
68. Aghajanova L, Velarde MC, Giudice LC. The progesterone receptor coactivator Hic-5 is involved in the pathophysiology of endometriosis. Endocrinology 2009;150:3863-70.
69. Wikstrom P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 2009;69:799-809.
70. Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003;56:280-6. (Pubitemid 36988748)
71. Jiang Y, Fleet JC. Phorbol esters enhance 1a,25-dihydroxyvitamin D3-regulated 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) gene expression through ERK-mediated phosphorylation of specific protein 3 (Sp3) in Caco-2 cells. Mol Cell Endocrinol 2012;361:31-9.
72. Tashiro K, Ishii C, Ryoji M. Role of distal upstream sequence in vitamin D-induced expression of human CYP24 gene. Biochem Biophys Res Commun 2007;358:259-65. (Pubitemid 46719112)
73. Ghogomu SM, van Venrooy S, Ritthaler M, Wedlich D, Gradl D. HIC-5 is a novel repressor of lymphoid enhancer factor/T-cell factor-driven transcription. J Biol Chem 2006;281:1755-64.
74. Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R. An elevated bax/ bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999;6:48-54. (Pubitemid 29051854)